These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38403634)

  • 1. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
    Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
    J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma.
    Li W; Zheng C; Xu X; Xia Y; Zhang K; Huang A; Zhang X; Zheng Y; Chen G; Zhang S
    Cell Mol Biol Lett; 2024 Apr; 29(1):50. PubMed ID: 38594618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
    Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
    Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression.
    Chen Z; Yuan J; Xu Y; Zhang C; Li Z; Gong J; Li Y; Shen L; Gao J
    Front Pharmacol; 2021; 12():757994. PubMed ID: 35069192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
    Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
    J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
    Yang H; Li H; Lu S; Shan S; Guo Y
    Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
    Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
    Ma N; Zhao Y
    Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Golgi phosphoprotein 3 promotes ovarian cancer progression and is associated with cisplatin resistance.
    Liu T; Jin ZW; Li Y; Zhang G; Yang XY; Xu XM; Ma YC
    J Cancer Res Ther; 2022 Apr; 18(2):488-495. PubMed ID: 35645119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.
    Hong X; Chen X; Wang H; Xu Q; Xiao K; Zhang Y; Chi Z; Liu Y; Liu G; Li H; Fang J; Lin T; Zhang Y
    Adv Sci (Weinh); 2023 Nov; 10(32):e2302377. PubMed ID: 37824205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/β-Catenin Pathway.
    Zhu J; Hu H; Wang J; Yang Y; Yi P
    Cell Physiol Biochem; 2018; 49(2):696-705. PubMed ID: 30165366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
    Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. REG3A promotes proliferation and DDP resistance of ovarian cancer cells by activating the PI3K/Akt signaling pathway.
    Jiang L; Liu Y; Liu M; Zheng Y; Chen L; Shan F; Ji J; Cao Y; Kai H; Kang X
    Environ Toxicol; 2024 Jan; 39(1):85-96. PubMed ID: 37665173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
    Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of Long Noncoding RNA H19 Downregulates miR-140-5p and Activates PI3K/AKT Signaling Pathway to Promote Invasion, Migration and Epithelial-Mesenchymal Transition of Ovarian Cancer Cells.
    Xu H; Ding Y; Yang X
    Biomed Res Int; 2021; 2021():6619730. PubMed ID: 34250088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway.
    Li M; Zhang W; Wang Y; Huang K; Sun T; Qiu Z; Yang L; Wu M; Zhang X; Zhang W
    Dis Markers; 2022; 2022():1941077. PubMed ID: 35978887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis.
    Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
    J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling.
    Li M; Hu M; Wang Y; Xia Z; Li Z; Li J; Zheng D; Zheng X; Xi M
    Biochem Biophys Res Commun; 2022 Dec; 637():348-357. PubMed ID: 36423381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M; Wang J; Guo Y; Yue H; Zhang L
    J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.